Seventeen cases of acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and combination chemotherapy at Tokyo Metropolitan Komagome Hospital between 1992 and 1999 were reviewed, and divided into 2 kary-otype-based cytogenetic groups. One group comprised 7 patients with either the typical t(15;17) alone or a normal karyotype, and the other group comprised 10 patients with additional karyotypic abnormalities. No patient had received prior chemotherapy or irradiation, and no cases were complicated by a history of myelodysplastic syndrome before the diagnosis of APL. There were no significant differences in clinical characteristics at disease presentation. Complete remission was achieved in all 17 patients and karyotypes of bone marrow cells normalized in all cases. No differences were found in relapse rate, overall survival, or disease-free survival between the 2 groups.
The analysis did not reveal any significant effect of additional chromosomal abnormalities on the prognosis of APL patients undergoing treatment with ATRA. However, a small number of patients were assessed in this study, and further cumulative studies are needed.
Berger R, Le Coniat M, Derre J, Vecchione D, Jonveaux P. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities.Genes Chromosomes Cancer. 1991;3:332–337.CrossRefPubMedPubMedCentralGoogle Scholar
Schoch C, Haase D, Haferlach T, et al. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients.Br J Haematol. 1996;94:493–500.CrossRefPubMedPubMedCentralGoogle Scholar
Slack JL, Arthur DC, Lawrence D, et al. Secondary cytogenetic changes in acute promyelocytic leukemia—prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a cancer and leukemia group B study.J Clin Oncol. 1997;15:1786–1795.CrossRefPubMedPubMedCentralGoogle Scholar
Pandolfi PP, Alcalay M, Fagioli M, et al. Genomic variability and alternative splicing generate multiple PML/RARa transcripts that encode aberrant PML proteins and PML/RARa isoforms in acute promyelocytic leukaemia.EMBO J. 1992;11:1397–1407.PubMedPubMedCentralGoogle Scholar
Huang W, Sun GL, Li XS, et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RARa isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse.Blood. 1993;82:1264–1269.Google Scholar
Kanamaru A, Takemoto Y, Tanimoto M, et al.All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia.Blood. 1995;85:1202–1206.PubMedGoogle Scholar
Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy.Blood. 1997;90:1014–1021.PubMedGoogle Scholar
Avvisati G, Coco FL, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study.Blood. 1996;88:1390–1398.PubMedGoogle Scholar
Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia.Blood. 1999;94:1192–1200.PubMedGoogle Scholar
Ogawa K, Shineha H, Abe R, et al. Acute promyelocytic leukemia with a history of RAEB in transformation and the 15/17 translocation.Jpn J Clin Hematol. 1989;30:67–71.Google Scholar
Dalton, Jr. WT, Cork A, Stass SA, Trujillo JM. Chronic myelomonocytic leukemia with trisomy 8 and related clone with trisomy 8 and t(15;17).Cancer Genet Cytogenet. 1988;32:287–292.CrossRefPubMedGoogle Scholar
Detourmignies L, Castaigne S, Stoppa AM, et al. Therapy-related acute promyelocytic leukemia: a roport on 16 cases.J Clin Oncol. 1992;10:1430–1435.CrossRefPubMedGoogle Scholar
Bhavnani M, Al Azzawi S, Liu Yin JA, Lucas GS. Therapy-related acute promyelocytic leukaemia.Br J Haematol. 1994;86:231–232.CrossRefPubMedGoogle Scholar